Radiotherapy for Head and Neck Cancer with Simultaneous Integrated Boost
Simultaneous Integrated Boost in the Primary and Adjuvant Therapy of Head and Neck Cancer: Quality Control Registry Prospective Longitudinal Obervation Trial
This study is testing a new type of radiation therapy for people with head and neck cancer to see if it helps them live longer and feel better while causing fewer side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wuerzburg University Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Würzburg, Bavaria) |
| Trial ID | NCT06831903 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the efficacy and safety of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in patients with head and neck cancers. It aims to assess local and regional control, overall survival, metastasis-free survival, and therapy-related toxicities while documenting patient-reported quality of life. The study follows a prospective, longitudinal design, collecting real-world outcomes and quality measures in accordance with clinical guidelines. Patients with confirmed malignancies will receive individualized treatment plans designed to minimize toxicity while effectively targeting high-risk tumor areas.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed malignant head and neck tumors who are undergoing definitive or adjuvant radio(chemo)therapy.
Not a fit: Patients with basal cell carcinoma or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes and quality of life for patients with head and neck cancers.
How similar studies have performed: Other studies utilizing similar SIB techniques have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 and older with histologically confirmed malignant head and neck tumors, undergoing definitive or adjuvant radio(chemo)therapy at the University Hospital Würzburg Exclusion Criteria: * missing informed consent * mental or physical disorders leading to inability to understand and/or fill the quationary * judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures
Where this trial is running
Würzburg, Bavaria
- University Clinic of Wuerzburg — Würzburg, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Victor Lewitzki, MD, PhD — University Clinic of Wuerzburg, Department of Radiation Oncology
- Study coordinator: Victor Lewitzki, MD, PhD
- Email: lewitzki_v@ukw.de
- Phone: +49-931-201-28869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.